EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The rapid assessment for prostate imaging and diagnosis ( RAPID ) prostate cancer diagnostic pathway

David Eldred-Evans iD, Martin J Connor, Mariana Bertoncelli Tanaka iD, Edward Bass, Deepika Reddy iD, Uma Walters iD, Luke Stroman iD, Easter Espinosa, Raj Das, Nalin Khosla, Henry Tam, Elizabeth Pegers und 4 weitere

BJU International · 2023-04 · 131 (4) · 461-470

DOI: 10.1111/bju.15899 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 10.11.2022. Verfasst von David Eldred-Evans und 15 weiteren Autor:innen. Beteiligte Einrichtung: Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To report outcomes within the Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) diagnostic pathway, introduced to reduce patient and healthcare burdens and standardize delivery of pre‐biopsy multiparametric magnetic resonance imaging (MRI) and transperineal biopsy. Patients and Methods A total of 2130 patients from three centres who completed the RAPID pathway (3 April 2017 to 31 March 2020) were consecutively entered as a prospective registry. These patients were also compared to a pre‐RAPID cohort of 2435 patients. Patients on the RAPID pathway with an MRI score 4 or 5 and those with PSA density ≥0.12 and an MRI score 3 were advised to undergo a biopsy. Primary outcomes were rates of biopsy and cancer detection. Secondary outcomes included comparison of transperineal biopsy techniques, patient acceptability and changes in time to diagnosis before and after the introduction of RAPID.

Results

The median patient age and PSA level were 66 years and 6.6 ng/mL, respectively. Biopsy could be omitted in 43% of patients (920/2130). A further 7.9% of patients (168/2130) declined a recommendation for biopsy. The percentage of biopsies avoided among sites varied (45% vs 36% vs 51%; P < 0.001). In all, 30% (221/742) had a local anaesthetic (grid and stepper) transperineal biopsy. Clinically significant cancer detection (any Gleason score ≥3 + 4) was 26% (560/2130) and detection of Gleason score 3 + 3 alone constituted 5.8% (124/2130); detection of Gleason score 3 + 3 did not significantly vary among sites ( P = 0.7). Among participants who received a transperineal targeted biopsy, there was no difference in cancer detection rates among local anaesthetic, sedation and general anaesthetic groups. In the 2435 patients from the pre‐RAPID cohor, time to diagnosis was 32.1 days (95% confidence interval [CI] 29.3–34.9) compared to 15.9 days (95% CI 12.9–34.9) in the RAPID group. A total of 141 consecutive patient satisfaction surveys indicated a high satisfaction rate with the pathway; 50% indicated a preference for having all tests on a single day.

Conclusions

The RAPID prostate cancer diagnostic pathway allows 43% of men to avoid a biopsy while preserving good detection of clinically significant cancers and low detection of insignificant cancers, although there were some centre‐level variations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansProstate-Specific AntigenAnesthetics, LocalImage-Guided BiopsyMagnetic Resonance Imaging

Stichwörter der Autor:innen

#PCSM#ProstateCancer#urooncPSAmultiparametric MRIprostate cancertargeted biopsytransperineal biopsy

Substanzen

Prostate-Specific AntigenAnesthetics, Local

Autor:innen und Institutionen

  • Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
  • Imperial Urology, Imperial College Healthcare NHS Trust, London, UK.
  • St George's University Hospitals NHS Foundation Trust, London, UK.
  • Epsom and St Helier University Hospitals, London, UK.
  • RM Partners West London Cancer Alliance, London, UK.

ORCID-Profile: David Eldred-Evans, Mariana Bertoncelli Tanaka, Deepika Reddy, Uma Walters, Luke Stroman, Hashim U Ahmed

Förderung

  • Wellcome Trust

Zitieren

APA

Eldred-Evans, D., Connor, M. J., Bertoncelli Tanaka, M., Bass, E., Reddy, D., Walters, U., Stroman, L., Espinosa, E., Das, R., Khosla, N., Tam, H., Pegers, E., Qazi, H., Gordon, S., Winkler, M., & Ahmed, H. U. (2023). The rapid assessment for prostate imaging and diagnosis ( RAPID ) prostate cancer diagnostic pathway. BJU International, 131(4), 461-470. https://doi.org/10.1111/bju.15899

Vancouver

Eldred-Evans D, Connor MJ, Bertoncelli Tanaka M, Bass E, Reddy D, Walters U, et al. The rapid assessment for prostate imaging and diagnosis ( RAPID ) prostate cancer diagnostic pathway. BJU International. 2023;131(4):461-470. doi:10.1111/bju.15899

BibTeX
@article{EldredEvans2023,
  author = {Eldred-Evans, David and Connor, Martin J and Bertoncelli Tanaka, Mariana and Bass, Edward and Reddy, Deepika and Walters, Uma and Stroman, Luke and Espinosa, Easter and Das, Raj and Khosla, Nalin and Tam, Henry and Pegers, Elizabeth and Qazi, Hasan and Gordon, Stephen and Winkler, Mathias and Ahmed, Hashim U},
  title = {The rapid assessment for prostate imaging and diagnosis ( RAPID ) prostate cancer diagnostic pathway},
  journal = {BJU International},
  year = {2023},
  volume = {131},
  number = {4},
  pages = {461--470},
  doi = {10.1111/bju.15899}
}
Kostenlos starten →